Pacific Biosciences of California, Inc. (PACB) Q2 2026 Earnings Call Transcript

SA Transcripts 161.55K Followers Follow Pacific Biosciences of California, Inc. ( PACB ) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDT Company Participants Christian Henry - President, CEO & Director Mark Van Oene - Chief Operating Officer James Gibson - CFO & Principal Accounting Officer Conference Call Participants Caylene Parrish Kyle Mikson - Canaccord Genuity Corp., Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Jack Meehan - Operon Research, LLC Mason Carrico - Stephens Inc., Research Division Pradeep Ambrose - TD Cowen, Research Division Skye Gilbert - Piper Sandler & Co., Research Division Lauren Timmins - Jefferies LLC, Research Division Luke Sergott - Barclays Bank PLC, Research Division Presentation Operator Good day. And welcome to PacBio's Second Quarter of 2026 Earnings Call. [Operator Instructions] Also, please be aware that today's call is being recorded. I'd now like to turn the call over to Caylene Parrish from Gilmartin Group. Please go ahead. Caylene Parrish Good afternoon, and welcome to PacBio's Second Quarter 2026 Earnings Conference Call. With me today are Mark Van Oene, President and Chief Executive Officer, Jim Gibson, Chief Financial Officer, and Christian Henry, PacBio board member and advisor. Earlier today, we issued a press release outlining the financial results we'll be discussing on today's call, a copy of which is available on the Investors section of our website at www.pacb.com or as furnished on Form 8-K, available on the Securities and Exchange Commission website at www.sec.gov. A copy of our earnings presentation is also available on the Investors section of our website. On today's call, we will make forward-looking statements including, among others, statements providing predictions, estimates, expectations, and guidance. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause our actual results to differ materially from those projected or discussed. Please review our SEC filings, including our most recent Form 10-Q and 10-K and our press releases, to